Insulin-like Growth Factor-2 (IGF2) is important for the regulation of human embryonic growth and development, and for adults' physiology. Incorrect processing of the IGF2 precursor, pro-IGF2(156), leads to the formation of two IGF2 proforms, big-IGF2(87) and big-IGF2(104). Unprocessed and mainly non-glycosylated IGF2 proforms are found at abnormally high levels in certain diseases, but their mode of action is still unclear. Here, we found that pro-IGF2(156) has the lowest ability to form its inactivating complexes with IGF-Binding Proteins and has higher proliferative properties in cells than IGF2 and other IGF prohormones. We also showed that big-IGF2(104) has a seven-fold higher binding affinity for the IGF2 receptor than IGF2, and that pro-IGF2(87) binds and activates specific receptors and stimulates cell growth similarly to the mature IGF2. The properties of these pro-IGF2 forms, especially of pro-IGF2(156) and big-IGF2(104), indicate them as hormones that may be associated with human diseases related to the accumulation of IGF-2 proforms in the circulation.

Department of Biochemistry Faculty of Science Charles University 12800 Prague 2 Czech Republic

Department of Cell Biology Faculty of Science Charles University 12800 Prague 2 Czech Republic

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Flemingovo nám 2 116 10 Prague 6 Czech Republic

Institute of Physiology Czech Academy of Sciences Vídeňská 1083 Prague 4 Czech Republic

York Structural Biology Laboratory Department of Chemistry University of York Heslington York YO10 5DD UK

See more in PubMed

LeRoith, D., Holly, J. M. P. & Forbes, B. E. Insulin-like growth factors: Ligands, binding proteins, and receptors. Mol. Metab. 52, 101245 (2021). PubMed PMC

Cianfarani S. Insulin-like growth factor-II: new roles for an old actor. Front. Endocrinol. 2012;3:118. PubMed PMC

Holly, J. M. P., Biernacka, K. & Perks, C. M. The neglected insulin: IGF-II, a metabolic regulator with implications for diabetes, obesity, and cancer. Cells8, 1207 (2019). PubMed PMC

Frago S, et al. Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist. Proc. Natl Acad. Sci. USA. 2016;113:E2766–E2775. PubMed PMC

Duguay SJ, et al. Post-translational processing of the insulin-like growth factor-2 precursor - Analysis of O-glycosylation and endoproteolysis. J. Biol. Chem. 1998;273:18443–18451. PubMed

Marks AG, Carroll JM, Purnell JQ, Roberts CT. Plasma distribution and signaling activities of IGF-II precursors. Endocrinology. 2011;152:922–930. PubMed PMC

Qiu Q, et al. Mature IGF-II prevents the formation of “big” IGF-II/IGFBP-2 complex in the human circulation. Growth Horm. IGF Res. 2010;20:110–117. PubMed

LeRoith D. Insulin-like growth factors. Seminars in Medicine of the Beth Israel Deaconess Medical Center. 2006;336:633–640. PubMed

Villareal DT, Murphy WA, Teitelbaum SL, Arens MQ, Whyte MP. Painful diffuse osteosclerosis after intravenous drug-abuse. Am. J. Med. 1992;93:371–381. PubMed

Khosla S, Ballard FJ, Conover CA. Use of site-speciftic antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis. J. Clin. Endocrinol. Metab. 2002;87:3867–3870. PubMed

Khosla S, et al. Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis - Potential insights into increasing bone mass in adults. J. Clin. Invest. 1998;101:2165–2173. PubMed PMC

Arakawa, Y. et al. Overexpression of IGF2 and IGF2 receptor in malignant solitary fibrous tumor with hypoglycemia: a case report. Surg. Case Rep. 4, 106 (2018). PubMed PMC

Daughaday WH, Trivedi B, Baxter RC. Serum big insulin-like growth factor-ii from patients with tumor hypoglycemia lacks normal E-domain O-linked glycosylation, a possible determinant of normal propeptide processing. Proc. Natl Acad. Sci. USA. 1993;90:5823–5827. PubMed PMC

Frystyk J, Skjaerbaek C, Zapf J, Orskov H. Increased levels of circulating free insulin-like growth factors in patients with non-islet cell tumour hypoglycaemia. Diabetologia. 1998;41:589–594. PubMed

Jannin A, et al. Non-islet-cell tumour hypoglycaemia (NICTH): about a series of 6 cases. Ann. Endocrinol.-Paris. 2019;80:21–25. PubMed

Ono, M. et al. A case of nonislet cell tumor hypoglycemia associated with malignant mesothelioma requiring a multifaceted approach for optimal glycemic control. Clin. Case Rep. 9, e05028 (2021). PubMed PMC

Dynkevich Y, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr. Rev. 2013;34:798–826. PubMed

De Groot JWB, et al. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocr.-Relat. Cancer. 2007;14:979–993. PubMed

Zapf J, Futo E, Peter M, Froesch ER. Can big insulin-like growth factor-ii in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia. J. Clin. Invest. 1992;90:2574–2584. PubMed PMC

Fukuda I, et al. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm. IGF Res. 2006;16:211–216. PubMed

Hizuka N, et al. Serum high molecular weight form of insulin-like growth factor II from patients with non-islet cell tumor hypoglycemia is O-glycosylated. J. Clin. Endocrinol. Metabol. 1998;83:2875–2877. PubMed

Iglesias P, Diez JJ. A clinical update on tumor-induced hypoglycemia. Eur. J. Endocrinol. 2014;170:R147–R157. PubMed

Jones JI, Clemmons DR. Insulin-like growth-factors and their binding-proteins - biological actions. Endocr. Rev. 1995;16:3–34. PubMed

Kim, H. et al. Structural basis for assembly and disassembly of the IGF/IGFBP/ALS ternary complex. Nat. Commun. 13, 4434 (2022). PubMed PMC

van Doorn, J. Insulin-like growth factor-II and bioactive proteins containing a part of the E-domain of pro-insulin-like growth factor-II. Biofactors46, 563–578 (2020). PubMed PMC

van Veggel KM, Huits RMHG, Donker GH, Lentjes EGWM, van Doom J. Column chromatographic characterization of complex formation of pro-IGF-II isoforms with acid labile subunit and IGF-binding proteins associated with non-islet cell tumour induced hypoglycaemia. Growth Horm. IGF Res. 2014;24:233–238. PubMed

Daughaday WH, Trivedi B, Baxter RC. Abnormal serum Igf-Ii transport in non-islet cell tumor hypoglycemia results from abnormalities of both igf binding protein-3 and acid-labile subunit and leads to elevation of serum-free Igf-Ii. Endocrine. 1995;3:425–428. PubMed

Bond JJ, Meka S, Baxter RC. Binding characteristics of pro-insulin-like growth factor-II from cancer patients: binary and ternary complex formation with IGF binding proteins-1 to -6. J. Endocrinol. 2000;165:253–260. PubMed

Yang CQ, Zhan X, Hu XG, Kondepudi A, Perdue JF. The expression and characterization of human recombinant proinsulin-like growth factor II and a mutant that is defective in the O-glycosylation of its E domain. Endocrinology. 1996;137:2766–2773. PubMed

Christofilis MA, et al. Study of serum big-insulin-like growth factor (IGF)-II and IGF binding proteins in two patients with extrapancreatic tumor hypoglycemia, using a combination of Western blotting methods. Eur. J. Endocrinol. 1998;139:317–322. PubMed

Rieunier G, et al. Bad to the bone: the role of the insulin-like growth factor axis in osseous metastasis. Clin. Cancer Res. 2019;25:3479–3485. PubMed

Kawai M, Rosen CJ. The insulin-like growth factor system in bone basic and clinical implications. Endocrinol. Metabol. Clin. North Amer. 2012;41:323. PubMed PMC

Potalitsyn, P. et al. A radioligand binding assay for the insulin-like growth factor 2 receptor. PLoS ONE15, e0238393 (2020). PubMed PMC

Hexnerova R, et al. Probing receptor specificity by sampling the conformational space of the insulin-like growth factor II C-domain. J. Biol. Chem. 2016;291:21234–21245. PubMed PMC

McKinnon T, Chakraborty C, Gleeson LM, Chidiac P, Lala PK. Stimulation of human extravillous trophoblast migration by IGF-II is mediated by IGF type 2 receptor involving inhibitory G protein(s) and phosphorylation of MAPK. J. Clin. Endocrinol. Metabol. 2001;86:3665–3674. PubMed

Hawkes C, et al. Single transmembrane domain insulin-like growth factor-II/mannose-6-phosphate receptor regulates central cholinergic function by activating a G-protein-sensitive, protein kinase C-dependent pathway. J Neurosci. 2006;26:585–596. PubMed PMC

Chu CH, et al. IGF-II/mannose-6-phosphate receptor signaling induced cell hypertrophy and atrial natriuretic peptide/BNP expression via G alpha q interaction and protein kinase C-alpha/CaMKII activation in H9c2 cardiomyoblast cells. J. Endocrinol. 2008;197:381–390. PubMed

Simonsen JL, et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat. Biotechnol. 2002;20:592–596. PubMed

Daughaday WH, et al. Synthesis and secretion of insulin-like growth factor-Ii by a leiomyosarcoma with associated hypoglycemia. New Engl. J. Med. 1988;319:1434–1440. PubMed

Kawai S, et al. Imbalanced expression of IGF2 and PCSK4 is associated with overproduction of big IGF2 in SFT with NICTH: a pilot study. J. Clin. Endocrinol. Metabol. 2018;103:2728–2734. PubMed

Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical review. J. Clin. Endocrinol. Metabol. 2014;99:713–722. PubMed PMC

Daughaday WH, Trivedi B. Unglycosylated big igf-ii in nonislet cell tumor hypoglycemia (Nicth) and Its serum binding. Int. Congr. Ser. 1994;1056:77–84.

Hikichi M, et al. A hypoglycemia-inducing giant borderline phyllodes tumor secreting high-molecular-weight insulin-like growth factor II: immunohistochemistry and a western blot analysis. Internal Med. 2018;57:237–241. PubMed PMC

Honma H, et al. Non-islet cell tumor hypoglycemia is caused by big IGF-II in a patient with a carcinosarcoma of the uterus. Internal Med. 2015;54:3165–3169. PubMed

Williams C, et al. An exon splice enhancer primes IGF2:IGF2R binding site structure and function evolution. Science. 2012;338:1209–1213. PubMed PMC

Williams C, et al. Structural insights into the interaction of insulin-like growth factor 2 with IGF2R domain 11. Structure. 2007;15:1065–1078. PubMed

Sohma, Y. et al. Comparative properties of insulin-like growth factor 1 (IGF-1) and [Gly7D-Ala]IGF-1 prepared by total chemical synthesis. Angew. Chem.-Int. Ed. 47, 1102–1106 (2008). PubMed

Gill R, et al. Modelling of the disulphide-swapped isomer of human insulin-like growth factor-1: implications for receptor binding. Protein Eng. 1999;12:297–303. PubMed

Sato A, et al. 3-Dimensional structure of human insulin-like growth factor-I (Igf-I) determined by H-1-Nmr and distance geometry. Int. J. Pept. Protein Res. 1993;41:433–440. PubMed

Greenall SA, et al. Biochemical characterization of individual human glycosylated pro-insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer. J. Biol. Chem. 2013;288:59–68. PubMed PMC

Xu YB, et al. How IGF-II binds to the human type 1 insulin-like growth factor receptor. Structure. 2020;28:786. PubMed PMC

Wang, R., Qi, X. F., Schmiege, P., Coutavas, E. & Li, X. C. Marked structural rearrangement of mannose 6-phosphate/IGF2 receptor at different pH environments. Sci. Adv. 6, eaaz1466 (2020). PubMed PMC

Valenzano KJ, HeathMonnig E, Tollefsen SE, Lake M, Lobel P. Biophysical and biological properties of naturally occurring high molecular weight insulin-like growth factor II variants. J. Biol. Chem. 1997;272:4804–4813. PubMed

Hashimoto R, et al. Binding sites and binding properties of binary and ternary complexes of insulin-like growth factor-II (IGF-II), IGF-binding protein-3, and acid-labile subunit. J. Biol. Chem. 1997;272:27936–27942. PubMed

Baxter RC, et al. Regulation of the insulin-like growth-factors and their binding-proteins by glucocorticoid and growth-hormone in nonislet cell tumor hypoglycemia. J. Clin. Endocrinol. Metabol. 1995;80:2700–2708. PubMed

Daughaday WH, Kapadia M. Significance of abnormal serum binding of insulin-like growth factor-Ii in the development of hypoglycemia in patients with non-islet-cell tumors. Proc. Natl Acad. Sci. USA. 1989;86:6778–6782. PubMed PMC

Tani Y, et al. Defective expression of prohormone convertase 4 and enhanced expression of insulin-like growth factor II by pleural solitary fibrous tumor causing hypoglycemia. Endocr. J. 2008;55:905–911. PubMed

Alberini CM, Chen DY. Memory enhancement: consolidation, reconsolidation and insulin-like growth factor 2. Trends Neurosci. 2012;35:274–283. PubMed PMC

Steinmetz AB, Johnson SA, Iannitelli DE, Pollonini G, Alberini CM. Insulin-like growth factor 2 rescues aging-related memory loss in rats. Neurobiol. Aging. 2016;44:9–21. PubMed PMC

Stern SA, Alberini CM. Mechanisms of memory enhancement. Wires Syst. Biol. Med. 2013;5:37–53. PubMed PMC

Yu, X. W., Pandey, K., Katzman, A. C. & Alberini, C. M. A role for CIM6P/IGF2 receptor in memory consolidation and enhancement. Elife9, e54781 (2020). PubMed PMC

Machackova K, et al. Mutations at hypothetical binding site 2 in insulin and insulin-like growth factors 1 and 2 result in receptor- and hormone-specific responses. J. Biol. Chem. 2019;294:17371–17382. PubMed PMC

Micsonai A, et al. BeStSele: webserver for secondary structure and fold prediction for protein CD spectroscopy. Nucleic Acids Res. 2022;50:W90–W98. PubMed PMC

Micsonai A, et al. BeStSel: a web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra. Nucleic Acids Res. 2018;46:W315–W322. PubMed PMC

Kabsch W, Sander C. Dictionary of protein secondary structure - pattern-recognition of hydrogen-bonded and geometrical features. Biopolymers. 1983;22:2577–2637. PubMed

Mirdita M, et al. ColabFold: making protein folding accessible to all. Nat. Methods. 2022;19:679. PubMed PMC

Mirdita M, Steinegger M, Soding J. MMseqs2 desktop and local web server app for fast, interactive sequence searches. Bioinformatics. 2019;35:2856–2858. PubMed PMC

Jumper J, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583. PubMed PMC

Sell C, et al. Effect of a null mutation of the insulin-like growth-factor-I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol. Cell. Biol. 1994;14:3604–3612. PubMed PMC

Miura M, Surmacz E, Burgaud JL, Baserga R. Different effects on mitogenesis and transformation of a mutation at tyrosine-1251 of the insulin-like growth-factor-I receptor. J. Biol. Chem. 1995;270:22639–22644. PubMed

Frasca F, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin- like growth factor II receptor in fetal and cancer cells. Mol. Cell. Biol. 1999;19:3278–3288. PubMed PMC

Morcavallo A, et al. Insulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of insulin receptor isoform A. J. Biol. Chem. 2012;287:11422–11436. PubMed PMC

Záková, L. et al. Human insulin analogues modified at the B26 site reveal a hormone conformation that is undetected in the receptor complex. Acta Crystallogr D Biol Crystallogr.70, 2765–2774 (2014). PubMed PMC

Asai S, Zakova L, Selicharova I, Marek A, Jiracek J. A radioligand receptor binding assay for measuring of insulin secreted by MIN6 cells after stimulation with glucose, arginine, ornithine, dopamine, and serotonin. Anal. Bioanal. Chem. 2021;413:4531–4543. PubMed

Tencerova M, et al. Obesity-associated hypermetabolism and accelerated senescence of bone marrow stromal stem cells suggest a potential mechanism for bone fragility. Cell Rep. 2019;27:2050. PubMed

Design of Potent Mannose-6-Phosphate Derivatives as Ligands for CI-M6P/IGF2R Using Fluorescence Polarization Assay

Late-stage labeling of diverse peptides and proteins with iodine-125

The final walk with preptin